Publications

Is the FDA Too Conservative or Too Aggressive?: A Bayesian Decision Analysis of Clinical Trial Design

2019
Isakov, Leah, Andrew W. Lo, and Vahid Montazerhodjat (2019), Is the FDA Too Conservative or Too Aggressive?: A Bayesian Decision Analysis of Clinical Trial Design, Journal of Econometrics 211 (1), 117–136.

Optimal Financing for R&D-Intensive Firms

2018
Thakor, Richard T. and Andrew W. Lo (2018), Optimal Financing for R&D-Intensive Firms, Working Paper.

Alzheimer’s Disease is About to Become a Crisis. Here’s How California Could Lead

2018
Kosik, Kenneth S., and Andrew W. Lo (2018). Alzheimer’s Disease is About to Become a Crisis. Here’s how California Could Lead, Sacramento Bee, May 22.

Doing Well By Doing Good

2018
Lo, Andrew W. (2018), Doing Well by Doing Good, RISK, December 12.

New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review

2018
Das, Sonya, Raphaël Rousseau, Peter C. Adamson, and Andrew W. Lo (2018), New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review, JAMA Oncology 4 (9), 1274–1280.

Patient-Centered Clinical Trials

2018
Chaudhuri, Shomesh E., Martin P. Ho, Telba Irony, Murray Sheldon, and Andrew W. Lo (2018), Patient-Centered Clinical Trials, Drug Discovery Today 23 (2), 395–401.

Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology

2017
Montazerhodjat, Vahid, Shomesh E. Chaudhuri, Daniel J. Sargent, Andrew W. Lo (2017), Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology, JAMA Oncology 3 (9).

Sharing R&D Risk in Healthcare via FDA Hedges

2017
Jorring, Adam, Andrew W. Lo, Tomas Philipson, Manita Singh, and Richard T. Thakor (2017), Sharing R&D Risk in Healthcare via FDA Hedges, Working Paper.

Pricing for Survival in the Biopharma Industry: A Case Study of Acthar Gel and Questcor Pharmaceuticals

2017
Burnham, Terence C., Samuel Huang, and Andrew W. Lo (2017), Pricing for Survival in the Biopharma Industry: A Case Study of Acthar Gel and Questcor Pharmaceuticals, Journal of Investment Management 15 (4), 69–91.

Just How Good an Investment Is the Biopharmaceutical Sector?

2017
Thakor, Richard T., Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, and Andrew W. Lo (2017), Just How Good an Investment Is the Biopharmaceutical Sector?, Nature Biotechnology 35 (12), 1149–1157.

Re-Inventing Drug Development: A Case Study of the I-SPY 2 Breast Cancer Clinical Trials Program

2017
Das, Sonya, and Andrew W. Lo (2017), Re-Inventing Drug Development: A Case Study of the I-SPY 2 Breast Cancer Clinical Trials Program, Contemporary Clinical Trials 62, 168–174.

Accelerating Biomedical Innovation: A Case Study of the SPARK Program at Stanford University, School of Medicine

2017
Kim, Esther S., Paige M. C. Omura, and Andrew W. Lo (2017), Accelerating Biomedical Innovation: A Case Study of the SPARK Program at Stanford University, School of Medicine, Drug Discovery Today 22 (7), 1064–1068.

Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology

2017
Montazerhodjat, Vahid, Shomesh E. Chaudhuri, Daniel J. Sargent, and Andrew W. Lo (2017), Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology, JAMA Oncology 3 (9), e170123.

New Directions for the FDA in the 21st Century

2017
Lo, Andrew W. (2017), Discussion: New Directions for the FDA in the 21st Century, Biostatistics 18 (3), 404–407.

Letter to Senators Wyden and Grassley: Comment on Their Sovaldi Report

2016